Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme

被引：0
|
作者：
Vermeire, S. [1 ]
Rubin, D. T. [2 ]
Regueiro, M. D. [3 ]
Takeuchi, K. [4 ]
Walsh, A. [5 ]
Kotze, P. G. [6 ]
Charabaty, A. [7 ]
Goetsch, M. [8 ]
Lazin, K. [8 ]
Wu, J. [9 ]
Tsamos, G. [10 ]
Segovia, M. [11 ]
Branquinho, D. [11 ]
Danese, S. [12 ,13 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH USA
[4] Tsujinaka Hosp Kashiwanoha, IBD Ctr, Dept Gastroenterol, Kashiwa, Chiba, Japan
[5] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Pontificia Univ Catolica Parana PUCPR, IBD Outpatient Clin, Colorectal Surg Unit, Curitiba, Brazil
[7] Johns Hopkins Sch Med, Div Gastroenterol & Hepatol, Washington, DC USA
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Thessaloniki, Thessaloniki, Cent Macedonia, Greece
[11] Pfizer Inc, New York, NY USA
[12] IRCCS San Raffaele Hosp, Milan, Italy
[13] Univ Vita Salute San Raffaele, Div Gastroenterol & Endoscopy, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0057
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP018
引用
收藏
页码：i115 / i117
页数：3
相关论文
共 50 条
  • [1] Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials
    Vermeire, S.
    Peyrin-Biroulet, L.
    Panes, J.
    Regueiro, M.
    Kotze, P. G.
    Charabaty, A.
    Goetsch, M.
    Shan, K.
    Wu, J.
    McDonnell, A.
    Woolcott, J.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 619 - 619
  • [2] ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 2.5 YEARS OF POOLED SAFETY DATA FROM GLOBAL CLINICAL TRIALS
    Vermeire, Severine
    Peyrin-Biroulet, Laurent
    Panes, Julian
    Regueiro, Miguel D.
    Kotze, Paulo G.
    Charabaty, Aline
    Goetsch, Martina
    Shan, Kevin
    Wu, Joseph
    McDonnell, Aoibhinn
    Woolcott, John
    Danese, Silvio
    GASTROENTEROLOGY, 2023, 164 (06) : S207 - S207
  • [3] Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
    Sandborn, W. J.
    Panes, J.
    Panaccione, R.
    D'Haens, G. R.
    Sands, B. E.
    Su, C.
    Moscariello, M.
    Jones, T. V.
    Pedersen, R. D.
    Friedman, G. S.
    Lawendy, N.
    Chan, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S344 - S344
  • [4] Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials
    Sandborn, W. J.
    Panes, J.
    D'Haens, G. R.
    Sands, B. E.
    Su, C.
    Moscariello, M.
    Jones, T. V.
    Pedersen, R. D.
    Friedman, G. S.
    Lawendy, N.
    Chan, G.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S45 - S46
  • [5] Tofacitinib for the Treatment of Ulcerative Colitis: Up to 9.2 Years of Safety Data From the Global Clinical Program
    Panes, Julian
    D'Haens, Geert R.
    Sands, Bruce E.
    Ng, Siew C.
    Lawendy, Nervin
    Kulisek, Nicole
    Guo, Xiang
    Wu, Joseph
    Vranic, Ivana
    Panaccione, Remo
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S910 - S910
  • [6] TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
    Sandborn, William J.
    Panes, Julian
    Panaccione, Remo
    D'Haens, Geert R.
    Sands, Bruce E.
    Su, Chinyu
    Moscariello, Michele
    Jones, Thomas V.
    Pedersen, Ronald D.
    Friedman, Gary S.
    Lawendy, Nervin
    Chan, Gary
    GASTROENTEROLOGY, 2019, 156 (06) : S1097 - S1097
  • [7] TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 4.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
    Sandborn, William J.
    Panes, Julian
    D'Haens, Geert R.
    Sands, Bruce E.
    Su, Chinyu
    Moscariello, Michele
    Jones, Thomas V.
    Pedersen, Ronald D.
    Friedman, Gary S.
    Lawendy, Nervin
    Chan, Gary
    GASTROENTEROLOGY, 2018, 154 (06) : S178 - S178
  • [8] Tofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials
    Sandborn, William J.
    Panes, Julian
    D'Haens, Geert R.
    Sands, Bruce E.
    Panaccione, Remo
    Ng, Siew C.
    Jones, Thomas V.
    Lawendy, Nervin
    Kulisek, Nicole
    Mundayat, Rajiv
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S353 - S354
  • [9] Tofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials
    Sandborn, William
    D'Haens, Geert
    Sands, Bruce E.
    Panaccione, Remo
    Ng, Siew C.
    Lawendy, Nervin
    Kulisek, Nicole
    Guo, Xiang
    Mundayat, Rajiv
    Su, Chinyu
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S360 - S360
  • [10] Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program
    Regueiro, Miguel
    Vermeire, Severine
    Rubin, David T.
    Dubinsky, Marla C.
    Hart, Ailsa
    Wu, Joseph
    Green, Jesse
    Woolcott, John C.
    Gorelick, Kenneth J.
    McDonnell, Aoibhinn
    Lazin, Krisztina
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S817
12345